Allscripts 'evaluating strategic alternatives'

| | Health Exec | Digital Transformation

Allscripts Healthcare Solutions is evaluating strategic alternatives, according to a statement from CEO Glen Tullman.

"We are confirming today that in light of the ongoing interest expressed in the company by third parties, the company is evaluating strategic alternatives,” Tullman said in a release.  The company further stated that there could be no assurance that this process will result in any specific transaction and Allscripts does not intend to comment further publicly with respect to the evaluation of strategic alternatives unless a specific transaction is approved by its board. 

Allscripts also released its third quarter financial details which include a drop in bookings. The $161.9 million in bookings for this period compared with bookings of $266.8 million in the third quarter of 2011 and $194.1 million in the second quarter of 2012.

“While market uncertainty impacted our sales in the third quarter, we are pleased with our progress regarding important development initiatives,” said Tullman.

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.